… effects of ALN-AGT six months after single-dose administration. … of ALN-AGT to hypertensive
patients was generally well tolerated and resulted in profound reductions in serum AGT and …

… ALN-AGT, a subcutaneous investigational RNA interference (RNAi) therapeutic targeting
hepatic AGT … to assess the safety and tolerability of ALN-AGT, we conducted a multicenter study …

… – Severe and serious AE of prostate cancer reported in 1 patient who received 200 mg
ALN-… effect of ALN-AGT01 and potential durability of effect in lowering AGT beyond 3 months …

… The good news is that ALN-VSP02 is well-tolerated and has an antitumor activity. … protein
expressions of AGT in the liver were remarkably reduced and the blood levels of AGT and Ang …

… RNA interference technology, using synthetic structurally well-defined short double-stranded
RNA (small interfering RNA [… ALN-HSD is currently under evaluation in Phase I trials for this …

… , an RNAi therapeutic targeting angiotensinogen (AGT), in … the combination of ALN-APP
with BIIB080 or ALN-APP and … to track the therapeutic effects of ALN-APP and BIIB080 will be …

… RNA interference (RNAi), target degradation by RNase H-mediated cleavage, splicing
modulation, noncoding RNA … Initially, an intravenously administered LNP-formulated siRNA (ALN-…

… of oligonucleotide therapeutic functioned via RNA interference (RNAi), was approved by the
… called small interfering RNA (siRNA). siRNA is a class of double-stranded RNA molecule, 19…

… RNA translation and small interfering RNA (siRNA) that function via the RNA interference …
vehicle or AGT small interfering RNA (siRNA) during the final 3 wk (n=7 per group). Middle, …

… small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks a new era of RNA
interference (RNAi… may be best appreciated by reviewing experience with ALN-VSP, an anti-tumor …